We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0P20 market cap is 6.67B. The company's latest EPS is HUF 2.8581 and P/E is 15.74.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| HUF (HUF) | HUF (HUF) | HUF (HUF) | HUF (HUF) | HUF (HUF) | |
| Total Revenue | 1.42M | 450k | 450k | 450k | 451k |
| Operating Income | -17.59M | -13.14M | -15.97M | -21.08M | -97.13M |
| Net Income | 26.09M | 12.69M | 133.53M | 171.12M | 423.41M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| HUF (HUF) | HUF (HUF) | HUF (HUF) | HUF (HUF) | HUF (HUF) | |
| Total Assets | 3.61B | 5.17B | 5.31B | 5.48B | 5B |
| Total Liabilities | 4.57M | 4.96M | 10.04M | 8.76M | 42.42M |
| Total Equity | 3.6B | 5.17B | 5.3B | 5.47B | 4.96B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| HUF (HUF) | HUF (HUF) | HUF (HUF) | HUF (HUF) | HUF (HUF) | |
| Operating | 75.86M | -443.79M | -1.1B | -536.09M | -43.9M |
| Investing | -575k | -429k | N/A | N/A | -174k |
| Financing | 1.98B | 1.55B | N/A | N/A | -342M |
| Market Cap | 6.67B |
| Price to Earnings Ratio | 15.74 |
| Price to Sales Ratio | 15k |
| Price to Cash Ratio | 3.5 |
| Price to Book Ratio | 1.35 |
| Dividend Yield | - |
| Shares Outstanding | 148.15M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 45.00 |
| 52 Week Low | 45.00 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Nutex Befektetesi Nyrt |
| Address |
czir��ki street 24-32. building a. ii. em. 141 budapest |
| Website | https://www.nutex.hu |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
